Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios

Published:2019 Issue:24 Volume:10 Page:5903-5914
ISSN:1837-9664
Container-title:Journal of Cancer
language:en
Short-container-title:J. Cancer

Author:

Pizzuti Laura,Krasniqi Eriseld,Barchiesi Giacomo,Mazzotta Marco,Barba Maddalena,Amodio Antonella,Massimiani Gioia,Pelle Fabio,Kayal Ramy,Vizza Enrico,Grassadonia Antonino,Tomao Silverio,Venuti Aldo,Gamucci Teresa,Marchetti Paolo,Natoli Clara,Sanguineti Giuseppe,Ciliberto Gennaro,Vici Patrizia

Publisher

Ivyspring International Publisher

Subject

Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eribulin in breast cancer: Current insights and therapeutic perspectives;World Journal of Experimental Medicine;2024-06-20

2. Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment;Molecules;2023-11-09

3. Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft;Scientific Reports;2023-05-27

4. PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin;Frontiers in Bioscience-Landmark;2023-03-16

5. Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft;2023-02-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP